LOS ANGELES, December 18, 2009 – Marlin Equity Partners (“Marlin”) is pleased to announce that it has acquired Liquent, Inc. (“Liquent”) from Thomson Reuters. Liquent is a leading provider of software and related regulatory and clinical services to the life sciences industry. The company’s solutions enable its customers to expedite the regulatory submissions and approval process, improve speed to market, control costs and increase productivity.
“Marlin was a valued partner throughout the process,” said John Bellizzi, Vice President of Thomson Reuters Professional Division. “The company’s industry knowledge, corporate divestiture expertise and ability to execute with speed and certainty allowed for a seamless transaction.”
Rick Riegel, Liquent’s CEO, stated, “We are very excited to partner with a leading private equity firm. Marlin brings substantial financial resources along with deep domain expertise in the healthcare IT sector. With Marlin’s backing and our comprehensive software and service solutions, industry leadership, and focus on customer service, we look forward to accelerating our growth and ability to service the evolving and rapidly changing needs of the life sciences industry.”
“Marlin’s healthcare knowledge coupled with Liquent’s software and outsourcing capabilities positions us to help customers solve complex regulatory challenges,” stated Jim Brady, Healthcare Operating Partner at Marlin Equity Partners. “We are looking to make near-term strategic acquisitions to expand Liquent’s product and service offerings and enhance its value proposition to the industry.”
About Marlin Equity Partners
Marlin Equity Partners is a Los Angeles, California-based private investment firm with over $1 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs in special situations. Marlin invests in businesses across multiple industries that are in the process of undergoing varying degrees of operational, financial or market-driven change where its capital base, industry relationships and extensive network of operational resources significantly strengthens a company’s outlook and enhances value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 30 acquisitions. For more information, please visit www.marlinequity.com.
About Liquent
Liquent is a Horsham, PA-based provider of software and related regulatory and clinical services to the life sciences industry, helping to ensure its clients meet the strict standards of regulatory authorities across the world. Liquent aids clients in the achievement of quality, accuracy, and data integrity to deliver regulatory reports and submissions reliably and on time. As a result, life sciences companies rely on Liquent’s solutions to provide the software and services necessary to expedite the regulatory submissions and approval process, improve speed to market, control costs and increase productivity. Over the last decade, thousands of regulatory submissions have been produced using Liquent’s world-class products and expert services. For more information, please visit www.liquent.com.
For additional information, please contact Peter Spasov at (310) 364-0100 or via e-mail at pspasov@marlinequity.com.